Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $24.1 million.

  • Ligand Pharmaceuticals' Accumulated Expenses rose 5438.46% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 5438.46%. This contributed to the annual value of $27.9 million for FY2024, which is 12383.89% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Accumulated Expenses stood at $24.1 million, which was up 5438.46% from $17.5 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Accumulated Expenses ranged from a high of $27.9 million in Q4 2024 and a low of $7.3 million during Q2 2023
  • Over the past 5 years, Ligand Pharmaceuticals' median Accumulated Expenses value was $15.0 million (recorded in 2023), while the average stood at $15.6 million.
  • In the last 5 years, Ligand Pharmaceuticals' Accumulated Expenses plummeted by 4989.35% in 2023 and then surged by 12383.89% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Accumulated Expenses (Quarter) stood at $17.6 million in 2021, then dropped by 10.8% to $15.7 million in 2022, then fell by 20.5% to $12.5 million in 2023, then skyrocketed by 123.84% to $27.9 million in 2024, then dropped by 13.7% to $24.1 million in 2025.
  • Its last three reported values are $24.1 million in Q3 2025, $17.5 million for Q2 2025, and $23.5 million during Q1 2025.